Indoco Remedies Q1 FY27: Strong API Growth, Better Margins and Positive Outlook Despite USFDA Delay
Indoco Remedies Limited reported a steady performance in the first quarter of FY27, supported by growth in its domestic business, regulated international markets, and API division. During the earnings call, management highlighted improvements in operational efficiency, debt reduction, strong regulatory progress, and confidence in achieving better profitability over the coming quarters.
The company also clarified that while the long-awaited USFDA inspection is still pending, it remains optimistic about future growth and continues to strengthen its manufacturing capabilities.
Q1 FY27 Financial Highlights
Standalone Performance
- Revenue: ₹408.1 crore, up 5.8% YoY
- EBITDA: ₹42.2 crore
- EBITDA Margin: 10.3%, compared to 3.8% in the same quarter last year.
Consolidated Performance
- Revenue: ₹466.2 crore, up 8.2% YoY
- EBITDA: ₹41 crore
- EBITDA Margin: 8.8%, improving from 4.1% a year ago.
The improvement in profitability was mainly driven by cost optimisation and better operational efficiency.
API Business Emerged as the Biggest Growth Driver
One of the strongest highlights of the quarter was the API (Active Pharmaceutical Ingredient) business.
- API revenue increased 42.4% year-on-year to ₹52.1 crore.
- Management said the API division is becoming an important growth engine by supplying raw materials for regulated markets while improving supply chain security and reducing manufacturing costs.
The company expects API profitability to improve further from the fourth quarter as utilisation increases.
US Business Grew Strongly Despite Regulatory Challenges
Indoco’s US formulations business delivered impressive growth.
- US revenue increased 62.2% YoY to ₹45.9 crore.
However, the company is still awaiting a US FDA inspection of its sterile manufacturing facility.
Management confirmed:
- The plant is fully prepared.
- The company has been waiting for an inspection for over six months.
- New ophthalmic product launches remain on hold until the inspection is completed.
Despite this, existing products like Brimonidine, Dorzolamide, Glimepiride, and Allopurinol continue to perform well.
European Business Expected to Bounce Back
European sales remained largely flat during the quarter.
Management clarified that this was mainly due to shipment timing rather than weak demand.
The company currently has more than ₹250 crore worth of confirmed orders, indicating healthy demand.
Management expects Europe to return to normal growth in the coming quarters.
Domestic Business Remains Stable
Domestic formulations generated ₹204 crore during the quarter.
According to management:
- Growth in anti-infective and respiratory products slowed because the delayed monsoon reduced seasonal demand.
- Other therapeutic areas performed well, including:
- Gastrointestinal
- Urology
- Vitamins
- Dentistry
- Dermatology
The company continues to rank:
- 33rd in the Indian pharmaceutical market
- 20th in prescription volume
Cyclopam Nears ₹200 Crore Milestone
Indoco’s flagship brand Cyclopam continues to perform strongly.
The brand has grown 44% since 2022 and is now close to becoming a ₹200 crore brand.
Management also highlighted strong growth from several mid-sized brands including:
- SM Fibro
- Rexidin-M
- Oxipod CV
- Dropizin
These brands recorded a combined growth of 86%, providing the next phase of domestic expansion.
Cost Optimisation Is Improving Margins
A major positive from the quarter was significant operational improvement.
Management revealed that the company:
- Manufactured the same production volume using 26% fewer batches
- Reduced manufacturing workforce by nearly 900 employees
- Improved automation and packing efficiency
- Optimised utilities and production planning
These initiatives helped improve EBITDA margins despite higher raw material costs.
Management believes operational efficiencies will continue supporting profitability over future quarters.
Raw Material Costs Impacted Gross Margins
The company admitted that higher raw material prices, driven by global geopolitical issues, increased production costs.
- Cost of goods sold increased by roughly 200 basis points.
- Some impact is expected to continue during Q2 before normalising later in the year.
Debt Continues to Decline
Indoco is steadily reducing its debt burden.
- Total debt declined from ₹964 crore in March 2026 to approximately ₹930 crore.
- The company plans to repay:
- Around ₹110 crore during FY27
- Another ₹150 crore next year
Management expects stronger cash flows to support further debt reduction.
Regulatory Progress Across Manufacturing Plants
The company received several important regulatory milestones:
- Baddi Unit I completed the Malta Medicines Authority audit.
- Baddi Unit III received EU-GMP certification from Germany.
- Goa Plant I successfully cleared another Malta audit.
- The Stability Centre at Aurangabad completed a USFDA pre-approval inspection with zero observations.
These approvals strengthen Indoco’s global manufacturing credentials.
Limited Capex Planned
Unlike previous years, the company has largely completed its expansion cycle.
Management expects FY27 capital expenditure of only ₹40–50 crore, mainly for maintenance.
Lower capex should support better free cash flow and faster debt reduction.
Growth Outlook
Management remains optimistic about future growth and expects:
- Domestic business to grow at high single-digit to low double-digit rates.
- Export business to continue expanding.
- Europe to recover in coming quarters.
- API business to remain a key growth driver.
- Margins to improve gradually through operational efficiencies.
- Overall revenue growth of around 12–15% CAGR over the next few years.
The biggest near-term trigger remains the pending USFDA inspection, which could unlock fresh product approvals and accelerate growth in the US market.